Overview

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

Status:
ENROLLING_BY_INVITATION
Trial end date:
2040-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH
Phase:
PHASE3
Details
Lead Sponsor:
BioMarin Pharmaceutical
Treatments:
vosoritide